2/20/2024 0 Comments Nasdaq codx![]() With sufficient funds, Co-Diagnostics repurchased 2.9 million shares during the quarter at an average price of $3.61 per share. ![]() DisclaimerĬo-Diagnostics Inc (NASDAQ:CODX) posted financial results for the third quarter that revealed ample cash on hand, giving the company scope to further advance its Co-Dx PCR Home testing platform for infectious diseases.Īs of September 30, 2022, the Salt Lake City, Utah-based molecular diagnostics company, had cash, equivalents, and marketable securities of $86.5 million.Ĭo-Diagnostics reported that it had a cash flow from operations of $10.6 million for the nine months ended September 30, 2022, of which $1.1 million was generated in the 3Q. Nevertheless, all content published by Proactive is edited and authored by humans, in line with best practice in regard to content production and search engine optimisation. Proactive will on occasion use automation and software tools, including generative AI. The team also has access to and use technologies to assist and enhance workflows. Our human content creators are equipped with many decades of valuable expertise and experience. Proactive has always been a forward looking and enthusiastic technology adopter. The team delivers news and unique insights across the market including but not confined to: biotech and pharma, mining and natural resources, battery metals, oil and gas, crypto and emerging digital and EV technologies. This is content that excites and engages motivated private investors. We are experts in medium and small-cap markets, we also keep our community up to date with blue-chip companies, commodities and broader investment stories. Proactive news team spans the world’s key finance and investing hubs with bureaus and studios in London, New York, Toronto, Vancouver, Sydney and Perth. All our content is produced independently by our experienced and qualified teams of news journalists. Proactive financial news and online broadcast teams provide fast, accessible, informative and actionable business and finance news content to a global investment audience. She has also worked for Agency France Presse, Business Standard, and the Financial Times in London. Previously, as a senior writer for Forbes India based in New York she has interviewed Fortune 500 CEOs and reported on state visits to Washington from the White House. She has reported on markets, foreign policy, and business from North America, Asia, and Europe. Past performance is a poor indicator of future performance.Uttara is the Business News Editor at Proactive and oversees the creation of feature articles and marquee CEO interviews. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on or relating to the use of, or inability to use, or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. ![]() Under no circumstances does any information posted on represent a recommendation to buy or sell a security. Is not operated by a broker, a dealer, or a registered investment adviser. Its diagnostics systems enable molecular testing for organisms and genetic diseases by automating historically complex procedures in both the development and administration of tests. The firm uses its proprietary test design system and proprietary reagents to design and sell polymerase chain reaction diagnostic tests for diseases and pathogens starting with tests for tuberculosis, a drug resistant tuberculosis test, hepatitis B and C, Malaria, dengue, human immunodeficiency virus and Zika virus, all of which tests have been designed and validated in its laboratory. ![]() The company also sells diagnostic equipment from other manufacturers as self-contained lab systems (MDx device). Its reagents are used for diagnostic tests that function via the detection and/or analysis of nucleic acid molecules, such as deoxyribonucleic acid and ribonucleic acid. The firm is engaged in developing, manufacturing and marketing diagnostics technology. The company is headquartered in Salt Lake City, Utah and currently employs 101 full-time employees. engages in the development and innovation of molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |